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Abstracts 189levels have been found to correspond to cartilage lesions upon arthroscopic
evaluation [14e17]. Lesions found in T2-weighted images and T2 maps have
also been correlated with degradations of cartilage matrix (i.e., fibrillation,
clefts [14,15]). T1r describes longitudinal relaxation in the rotating frame,
and has been associated with proteoglycan loss, which is thought to precede
the development of symptomatic.
Assessment of bone quality in OA using MR and micro-computed tomography
(mCT) in bone samples has also revealed much information about bone
density and micro-architecture.
Although the disruptive and degradative events accompanying the advent of
disease progression in OA are known, the mechanisms and order in which
these events occur is still an active area of research. Preclinical studies
designed to address this need employ several animal models, which exhibit
disease phenotypes similar to those observed in humans. These studies will
be reviewed in this talk, and future directions will be identified.
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The XtremeCT (Scanco Medical AG, Bruttisellen, Switzerland) developed in
2004 was the first scanner to propose in vivo assessment of
trabecular microarchitecture at the ultradistal radius and tibia. At that
time we proposed a 2.8 min scan over a 9.02 mm region, with 82 mm voxel
size, for a radiation dose lower than 3 mSv [Laib et al e Bone 1999].
This was the chance to pursue at the in vivo and organic level all the bone
research done at the tissue level with restricted region of interest as per his-
tomorphometry. Various studies exploited this new opportunity to better un-
derstand the mechanisms of bone loss in osteoporosis or the actions of drugs
affecting bone metabolism.
During the past decade, applications focused on bone research are being
developed as cortical bone analysis, finite element analyses or
3D registration. But bone is not the only field that can take advantage
of the XtremeCT. Research in rheumatoid arthritis also finds interest
into bone erosions, or joint space width in 3D that can be obtained from
high resolution joint imaging [SPECTRA]. With the interest in sarcopenia
growing in the community, we are currently validating a method to
assess muscle volume to fully exploit the images obtained with XtremeCT,
even on the low density range [Erlandson et al e ASBMR 2012].
Vascular calcification may also be assessed, in addition to bone micro-
architecture changes in patients suffering chronic kidney disease, or
diabetes [Patsch].
Movement artifacts are known to affect XtremeCT scans, notably at the
radius. They impact the reproducibility of the measurements and reduce the
number of valid scans in longitudinal studies on bone fragility or osteoporosis
treatment efficacy [Pialat et al e Bone 2011].
This motivated the design of a new HR-pQCT scanner (XtremeCT II) to address
the movement artifacts issue. Hardware improvements allow for scan time
shortening with no cost on image quality, with two different scan protocols
over a 10 mm range. The basic protocol was specified to be compatible with
XtremeCT: 1.5 min scan, 82 mm voxel size and 3 mSv dose. The second protocol
has better resolution and is still acceptable for patient scans: 61 mmvoxel size,
2 min scan time and 5 mSv dose.
A set of 20 cadaver bone phantoms (EBS, UCSF) was scanned to compare
results across the different scan protocols, between XtremeCT II, XtremeCT
and mCT 100. We obtained excellent correlations between all datasets, andgood agreements were met between XtremeCT II both at 82 and 61 mm when
compared to XtremeCT. We also found that the accuracy of bone micro-
architecture measurements improved as the voxel size decreased, with
respect to mCT 100 results.
Reduced scan time should lead to significant improvements regarding
movement artifacts on in vivo scans. Also a new forearm cast will help to
limit patient mobility.
XtremeCT II is also able to scan at 30 mm voxel size, which may find use in ex
vivo studies or preclinical research involving relatively large animals such as
rabbits.
XtremeCT II does not only improve the research in osteoporosis, but is more
flexible hence widening the horizon of its applications.Brief CV
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